Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports
Shapiro, J.; Dean, N. E.; Madewell, Z. J.; Yang, Y.; Halloran, M. E.; Longini, I. M.
Show abstract
In this report, we provide summary estimates, from publications and reports, of vaccine efficacy (VE) for the COVID-19 vaccines that are being rolled out on a global scale. We find that, on average, the efficacy against any disease with infection is 85% (95% CI: 71 - 93%) after a fully course of vaccination. The VE against severe disease, hospitalization or death averages close to 100%. The average VE against infection, regardless of symptoms, is 84% (95% CI: 70 - 91%). We also find that the average VE against transmission to others for infected vaccinated people is 48% (95% CI: 45 - 52%). Finally, we prove summary estimates of the VE against any disease with infection for some of the variants of concern (VOC). The average VE for the VOC{gamma} (P1) is 61% (95% CI: 43 - 73%). The average VE for the VOC (B.1.1.7), {beta} (B.1.351), and{delta} (B.1.617.2) after dose 1 are 48% (95% CI: 44 - 51%), 35% (95% CI: -11 - 62%), and 33% (95% CI: 21 - 43%), respectively. The average VE for the VOC (B.1.1.7), {beta} (B.1.351), and{delta} (B.1.617.2) after dose 2 are 85% (95% CI: 25 - 97%), 57% (95% CI: 14 - 78%), and 78% (95% CI: 28 - 93%), respectively.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Interpreting vaccine efficacy trial results for infection and transmission 95%
- Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19 94%
- Cost-effectiveness of routine COVID-19 adult vaccination programmes in England 94%
Similar papers in this journal
- Beyond the new normal: assessing the feasibility of vaccine-based elimination of SARS-CoV-2 94%
- Evaluating the effects of vaccine rollout policies in European countries: A simulation study 93%
- Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States—January–April, 2021 93%
Similar papers in this journal
Similar papers in this journal
- Effectiveness of Covid-19 vaccines against SARS-CoV-2 Omicron variant (B.1.1.529): A systematic review with meta-analysis and meta-regression 93%
- Epidemiological differences in the impact of COVID-19 vaccination in the United States and China 93%
- Fall 2021 Resurgence and COVID-19 Seroprevalence in Canada Modelling waning and boosting COVID-19 immunity in Canada A Canadian Immunization Research Network Study 93%
Similar papers in this journal
- Assessing the feasibility of Phase 3 vaccine trials against Marburg Virus Disease: a modelling study 94%
- Benefit-Risk Assessment Of COVID-19 Vaccine, Mrna (Mrna-1273) For Males Age 18-64 Years 94%
- Evaluation of statistical models of carriage to predict the impact of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Nigeria 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.